US approval for Gileads 3 in 1 hepatitis C treatment

The FDA has recently approved Gilead Sciences’ triple drug therapy, Vosevi, to treat hepatitis C Virus (HCV) as a back-up therapy for patients who cannot treat the virus with current drugs. The single-tablet triple therapy contains NS5B polymerase inhibitor sofosbuvir and NS5A inhibitor velpatasvir. Which are the two active ingredients in Gilead’s recently-approved two-drug HCV

Continue Reading